Hematopoietic stem cell transplantation in pediatric patients with type VI mucopolysaccharidosis.

IF 3.2 Q1 PEDIATRICS Clinical and Experimental Pediatrics Pub Date : 2025-03-11 DOI:10.3345/cep.2024.02033

Vedat Uygun, Koray Yalçın, Hayriye Daloğlu, Seda Öztürkmen, Suna Çelen, Suleimen Zhumatayev, Gülsün Karasu, Akif Yeşilipek

{"title":"Hematopoietic stem cell transplantation in pediatric patients with type VI mucopolysaccharidosis.","authors":"Vedat Uygun, Koray Yalçın, Hayriye Daloğlu, Seda Öztürkmen, Suna Çelen, Suleimen Zhumatayev, Gülsün Karasu, Akif Yeşilipek","doi":"10.3345/cep.2024.02033","DOIUrl":null,"url":null,"abstract":"Background: It is uncertain whether hematopoietic stem cell transplantation (HSCT), versus standard enzyme replacement therapy (ERT), is effective for type VI mucopolysaccharidosis (MPS VI).Purpose: New related advances in HSCT prompted an examination of the transplant procedures performed in a recent cohort.Methods: This single-center retrospective study reviewed the medical records of 17 pediatric patients with MPS VI who underwent allogeneic HSCT in 2021-2023. All conditioning regimens were myeloablative. Engraftment days, complications, and survival data were recorded. As follow-up was short, we recorded only 6-min walk test distance before versus after HSCT.Results: The patients underwent transplantation at a median of 6 years post-diagnosis. All were engrafted and had a full or mixed chimerism. Enzyme levels were within normal ranges. Walking tests of all evaluable patients improved at a median 9-month follow-up.Conclusion: HSCT aims to improve the disease and provides a permanent solution at the enzyme level, eliminating enzyme replacement therapy. Our study showed that HSCT, a less expensive and permanent treatment option, should be offered to patients with MPS VI.","PeriodicalId":36018,"journal":{"name":"Clinical and Experimental Pediatrics","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3345/cep.2024.02033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: It is uncertain whether hematopoietic stem cell transplantation (HSCT), versus standard enzyme replacement therapy (ERT), is effective for type VI mucopolysaccharidosis (MPS VI).

Purpose: New related advances in HSCT prompted an examination of the transplant procedures performed in a recent cohort.

Methods: This single-center retrospective study reviewed the medical records of 17 pediatric patients with MPS VI who underwent allogeneic HSCT in 2021-2023. All conditioning regimens were myeloablative. Engraftment days, complications, and survival data were recorded. As follow-up was short, we recorded only 6-min walk test distance before versus after HSCT.

Results: The patients underwent transplantation at a median of 6 years post-diagnosis. All were engrafted and had a full or mixed chimerism. Enzyme levels were within normal ranges. Walking tests of all evaluable patients improved at a median 9-month follow-up.

Conclusion: HSCT aims to improve the disease and provides a permanent solution at the enzyme level, eliminating enzyme replacement therapy. Our study showed that HSCT, a less expensive and permanent treatment option, should be offered to patients with MPS VI.

查看原文